SFGV

The Week

Merck (MRK) closed the week at $147.76, up 0.7%. The S&P 500 gained 2.51% over the same stretch, leaving MRK about 1.81 percentage points behind. The stock opened Monday at $148.37 and touched a high of $149.31 before slipping to a weekly low near $145.24 on Tuesday. It then tested the $145 area twice more and settled back above $147 in a choppy, range-bound tape. Weekly turnover totalled 32.1 million shares, with average daily volume near 6.4 million shares, roughly 28% below the 60-day median, pointing to a quiet week overall.

Key Events

The week’s news flow centred on two pipeline updates. Early in the week, Merck reported positive Phase 2b results for efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis. The trial met its primary endpoint, with MASH resolution rates as high as 63% and no worsening of steatohepatitis. The stock rose Monday but still lagged the broader market. On Friday, Merck received a positive CHMP opinion from the EU for WELIREG (belzutifan) in combination with lenvatinib for advanced clear cell renal cell carcinoma, and for expanding the marketing authorisation of ENFLONSIA (clesrovimab) to children up to 24 months who remain vulnerable to severe RSV disease in their second RSV season. Merck also took part in the Jefferies Global Healthcare Conference. On the industry side, reports of near-term drug pricing pressure on Lilly and Gilead, plus a talc-related mesothelioma award against Johnson & Johnson, added to sector-wide noise.

Analyst Ratings

Across 28 covering firms, 14 rate Merck a buy and 5 rate it overweight, while 9 sit at hold; none have an underweight or sell rating. The consensus rating is buy, with a consensus target of $161.53, implying about 9.3% upside from the current price. Individual targets range from $105 to $186, a wide spread. Within the pharmaceutical industry’s 208 ranked names, Merck sits at No. 3.

The Week Ahead

On the macro front, the New York Fed manufacturing survey lands Monday, followed on Tuesday by retail sales, industrial production, import prices and the NAHB housing market index. Merck has no earnings due in the immediate window; the next release is fiscal fourth-quarter 2026 results in February 2027, before the open. The key follow-throughs to watch are whether the efinopegdutide data and EU regulatory wins gain further traction, and how the drug pricing story around Lilly and Gilead evolves from here.

In Short

This week’s price action tracked the news only loosely: pipeline data and EU regulatory progress arrived back-to-back, yet the stock eked out a small gain on light volume and clearly lagged the S&P 500. Valuation remains stretched at roughly 148.5x P/E and 8.11x P/B, while the consensus target still offers about 9% upside against a wide $105-$186 range of estimates. Latest-session flows show large-lot money as a net seller while retail-sized orders turned net buyers, a split in direction. The open questions are whether the market keeps pricing in the pipeline catalysts and whether sector-level drug pricing pressure continues to build.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.